Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces that all closing conditions in the collaboration and license agreement with Roche announced on March 12, 2025 have been satisfied, including regulatory conditions, and the agreement has become effective..

Zealand Pharma A/S是一家专注于发现和开发创新肽类药物的生物技术公司，今天宣布与罗氏（Roche）于2025年3月12日公布的协作和许可协议中的所有成交条件已经满足，包括监管条件，该协议现已生效。

“We are incredibly excited to launch this partnership, which represents a step change to realize Zealand Pharma’s vision of becoming a key player in the future management of obesity. Roche ticked all the right boxes for what we were looking for in a partner and we look very much forward to working closely together to unlock the full potential of petrelintide to benefit people who are overweight or obese”, said Adam Steensberg, Chief Executive Officer at Zealand Pharma. .

“我们非常兴奋地启动这一合作伙伴关系，这代表了实现Zealand Pharma成为未来肥胖管理领域重要参与者的愿景的一个重大转变。罗氏完全符合我们在合作伙伴中寻找的所有条件，我们非常期待紧密合作，充分释放petrelintide的潜力，造福超重或肥胖人群。” Zealand Pharma首席执行官Adam Steensberg表示。

About Zealand Pharma A/S

关于Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products..

Zealand Pharma A/S是一家专注于发现和开发生物肽药物的生物技术公司。Zealand发明的十多种候选药物已进入临床开发阶段，其中两种已上市，三种处于后期开发阶段。该公司与多家制药公司建立了开发合作关系，并为其上市产品建立了商业合作关系。

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Zealand成立于1998年，总部位于丹麦哥本哈根，在美国也有业务。有关Zealand的业务和活动的更多信息，请访问www.zealandpharma.com。

Contacts

联系人

Adam Lange (Investors)

亚当·兰格（投资者）

Vice President, Investor Relations

投资者关系副总裁

Zealand Pharma

捷灵亚制药

Email: alange@zealandpharma.com

电子邮件：alange@zealandpharma.com

Neshat Ahmadi (Investors)

纳什阿特·艾哈迈迪（投资者）

Investor Relations Manager

投资者关系经理

Zealand Pharma

Zealand制药公司

Email: neahmadi@zealandpharma.com

电子邮件：neahmadi@zealandpharma.com

Anna Krassowska, PhD (Investors and Media)

安娜·克拉索夫斯卡，博士（投资者与媒体）

Vice President, Investor Relations & Corporate Communications

副总裁，投资者关系与企业传播

Zealand Pharma

捷灵亚制药

Email: akrassowska@zealandpharma.com

电子邮件：akrassowska@zealandpharma.com

Source: globenewswire.com

来源：globenewswire.com